Skip to main content

Table 1 Clinical characteristics at diagnosis of the 6 R/R ALAL-NOS patients

From: Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified

No

Sex

Age (y)

Diagnosis

WBC (109/L)

BM blast cell(%)

Chromosome

Fish

Gene mutation(NGS)

1

F

66

ALAL-NOS

3.37

87.0

46,XX

Negative

RUNX1, FAT1, BCOR

2

M

16

ALAL-NOS

25.18

91.50

46, XY, t(10; 12)(p11.2; q15), inc[4]/ 46, XY

Negative

PHF6, NRAS, RAD21, CALR

3

M

23

ALAL-NOS

62.9

83.5

46,XY

Negative

PHF6 ; IKZF1 ; KMT2D ;WT1;PTPN11;EED

4

M

29

ALAL-NOS

2.36

68.0

46,XY

MLL(+)

IL7R

5

F

52

ALAL-NOS

5.57

73.5

46 XX,del(22)(q13)[3]/

46,XX,del(8)(p21),del(22)(q13)[15]/

46,XX,t(3;6),del(8)(p21),del(22)(q13)[1]/

46,XX[1]

Negative

BCOR

6

M

22

ALAL-NOS

55.5

79.0

47,XY,del(5)(q31),del(13)(?q12q22),+mar[20]

Negative

NOTCH1 KMT2C PTPN11 TP53